BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24563633)

  • 21. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of angiogenesis in solid tumours: an overview.
    Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
    Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neoplasms and angiogenesis].
    Lewy-Trenda I
    Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor as a target for anticancer therapy.
    Ferrara N
    Oncologist; 2004; 9 Suppl 1():2-10. PubMed ID: 15178810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting angiogenesis in cancer therapy.
    Ichihara E; Kiura K; Tanimoto M
    Acta Med Okayama; 2011 Dec; 65(6):353-62. PubMed ID: 22189475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF inhibition: insights from preclinical and clinical studies.
    Crawford Y; Ferrara N
    Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
    Cao Y
    Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
    Welti J; Loges S; Dimmeler S; Carmeliet P
    J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptation to antiangiogenic therapy in neurological tumors.
    Flanigan PM; Aghi MK
    Cell Mol Life Sci; 2015 Aug; 72(16):3069-82. PubMed ID: 25943307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
    Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers.
    Olejarz W; Kubiak-Tomaszewska G; Chrzanowska A; Lorenc T
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
    Bottsford-Miller JN; Coleman RL; Sood AK
    J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia: a key regulator of angiogenesis in cancer.
    Liao D; Johnson RS
    Cancer Metastasis Rev; 2007 Jun; 26(2):281-90. PubMed ID: 17603752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.